Ontology highlight
ABSTRACT:
SUBMITTER: Simonneau G
PROVIDER: S-EPMC4664609 | biostudies-literature | 2015 Dec
REPOSITORIES: biostudies-literature
Simonneau Gérald G Channick Richard N RN Delcroix Marion M Galiè Nazzareno N Ghofrani Hossein-Ardeschir HA Jansa Pavel P Le Brun Franck-Olivier FO Mehta Sanjay S Perchenet Loic L Pulido Tomás T Sastry B K S BK Sitbon Olivier O Souza Rogério R Torbicki Adam A Rubin Lewis J LJ
The European respiratory journal 20151022 6
In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts.Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (≤6 months; n=110) or prevalent (>6 months; n=157) ...[more]